We found, from the perspective of pharmacovigilance, that the IL-17 inhibitors SEC (ROR = 2.13, 95% CI [1.96-2.30]) and IXE (ROR = 2.79, 95% CI [2.39-3.27]) can trigger IBD, while BRO did not trigger safety signals. Here, IL17A is linked to inflammatory bowel disease.